Published in Vaccine Weekly, February 17th, 1997
The vaccine is being developed by a research team led by David B. Weiner of the University of Pennsylvania in collaboration with Apollon Inc., Malvern, Pennsylvania. Weiner's group has received a four-year, $4.2 million grant from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) to develop naked DNA for use as an AIDS therapy.
The so-called naked DNA vaccine consists of a gene construct, pM160-MN, that expresses the envelope glycoprotein of the MN strain of HIV-1 under the control of the human cytomegalovirus (CMV) promoter gene. The DNA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.